Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro
作者： He Liu , Hongyan Li , Zhiqiang Feng , Jun Tai , Yang Meng
DOI: 10.1080/10428190802709438
关键词:
摘要: FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), significantly inhibited the growth of imatinib-resistant different resistance mechanisms (K562/G5.0 and K562/G01), decreased expression autophosphorylation Bcr/Abl, c-Src Lyn kinases on them. It also proliferation Src over activated cells DU145 MDA-MB-231. Furthermore, potently prolonged survival time non-obese diabetic/severe combined immunodeficient mice harboured K562/G5.0 cells. These results indicated that FB2, an inhibitor, promising candidate for CML cancer.
sci-hub.se 参考文章(43)
Philipp le Coutre, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino, Carlo Gambacorti-Passerini, Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. ,vol. 95, pp. 1758- 1766 ,(2000) , 10.1182/BLOOD.V95.5.1758.005A41_1758_1766
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
Susanne Danhauser-Riedl, Bertold Emmerich, Michael Hallek, Brian J. Druker, Markus Warmuth, Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Research. ,vol. 56, pp. 3589- 3596 ,(1996)
Erica O'Bryan, Richard Jove, Purva Bali, Mei Huang, Thomas Loughran, Ramadevi Nimmanapalli, James Tepperberg, Pearlie Kay Burnette, Kapil Bhalla, Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin Cancer Research. ,vol. 62, pp. 5761- 5769 ,(2002)
Wolf-K. Hofmann, Letetia C. Jones, Nathan A. Lemp, Sven de Vos, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann, H. Phillip Koeffler, Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. ,vol. 99, pp. 1860- 1862 ,(2002) , 10.1182/BLOOD.V99.5.1860
Nicholas J. Donato, Ji Yuan Wu, Jonathan Stapley, Gary Gallick, Hui Lin, Ralph Arlinghaus, Moshe Talpaz, BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. ,vol. 101, pp. 690- 698 ,(2003) , 10.1182/BLOOD.V101.2.690
Elisabeth Buchdunger, Alex Matter, Brian J. Druker, Bcr-Abl inhibition as a modality of CML therapeutics. Biochimica et Biophysica Acta. ,vol. 1551, ,(2001) , 10.1016/S0304-419X(01)00022-1
Agata Klejman, Steven J Schreiner, Malgorzata Nieborowska-Skorska, Artur Slupianek, Matthew Wilson, Thomas E Smithgall, Tomasz Skorski, The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells The EMBO Journal. ,vol. 21, pp. 5766- 5774 ,(2002) , 10.1093/EMBOJ/CDF562
George D. Demetri, Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571) European Journal of Cancer. ,vol. 38, ,(2002) , 10.1016/S0959-8049(02)80603-7
Sangkil Nam, Donghwa Kim, Jin Q. Cheng, Shumin Zhang, Ji-Hyun Lee, Ralf Buettner, Janni Mirosevich, Francis Y. Lee, Richard Jove, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Research. ,vol. 65, pp. 9185- 9189 ,(2005) , 10.1158/0008-5472.CAN-05-1731